Form 4: Revolution Medicines Executive Exercises Stock Options and Reports Beneficial Ownership

Mark A. Goldsmith, President and CEO of Revolution Medicines, executed stock options and reported changes in beneficial ownership of company stock.

Summary

• On December 18, 2024, Mark A. Goldsmith, President and CEO of Revolution Medicines, exercised stock options to acquire 30,846 shares of common stock at a price of $0.49 per share.
• Following this transaction, Goldsmith directly owns 355,902 shares of common stock, including 167,125 restricted stock units.
• Goldsmith also has indirect ownership through several trusts: Jonathan Goldsmith Revocable Trust (20,424 shares), Rebecca Eve Goldsmith Trust (20,424 shares), and Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust (465,604 shares).

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing, reflecting standard executive compensation practices. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding the holdings of company insiders.

Comparison to Industry Standards

• Executive stock option exercises are a common form of compensation in the biotechnology industry.
• The reporting requirements outlined in Form 4 filings are standardized across all publicly traded companies in the United States, ensuring transparency in insider trading activities.
• Comparable companies such as Amgen, Gilead Sciences, and Vertex Pharmaceuticals also have executives who regularly report changes in their beneficial ownership through Form 4 filings.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding executive stock ownership.
• It reflects a component of executive compensation, potentially aligning management's interests with those of shareholders.

Key Dates